Squarepoint’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-7,421
Closed -$204K – 4658
2026
Q2
$204K Sell
7,421
-27,112
-79% -$721K ﹤0.01% 4056
2026
Q1
$927K Buy
+34,533
New +$1.03M ﹤0.01% 2830
2025
Q4
– Sell
-9,480
Closed -$291K – 4492
2025
Q3
$291K Sell
9,480
-84,753
-90% -$2.07M ﹤0.01% 3695
2025
Q2
$1.95M Buy
94,233
+81,434
+636% +$1.67M ﹤0.01% 2124
2025
Q1
$251K Sell
12,799
-104,708
-89% -$2.2M ﹤0.01% 3861
2024
Q4
$2.45M Buy
117,507
+108,705
+1,235% +$2.39M ﹤0.01% 2238
2024
Q3
$215K Buy
+8,802
New +$235K ﹤0.01% 3643
2024
Q2
– Sell
-19,116
Closed -$572K – 4275
2024
Q1
$572K Buy
19,116
+1,353
+8% +$39.7K ﹤0.01% 2955
2023
Q4
$566K Buy
17,763
+5,550
+45% +$174K ﹤0.01% 2912
2023
Q3
$431K Sell
12,213
-7,766
-39% -$296K ﹤0.01% 2905
2023
Q2
$759K Buy
19,979
+1,235
+7% +$49.2K ﹤0.01% 2366
2023
Q1
$708K Sell
18,744
-1,467
-7% -$56.4K ﹤0.01% 2106
2022
Q4
$857K Sell
20,211
-26,979
-57% -$1.11M ﹤0.01% 1925
2022
Q3
$1.52M Buy
+47,190
New +$1.66M 0.01% 1498
2021
Q1
– Sell
-9,231
Closed -$375K – 3294
2020
Q4
$375K Buy
+9,231
New +$345K ﹤0.01% 2040

Other funds holding GMAB

Squarepoint's GMAB Position: Q3 2026 in Review

Squarepoint sold out of Genmab (GMAB) in Q3 2026, closing a stake of 7,421 shares — an estimated $204K sold.

Squarepoint first reported a position in GMAB in Q4 2020 and held it in 15 quarters. The position peaked at $2.45M in Q4 2024. 204 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

  • Squarepoint reported no remaining Genmab position as of Q3 2026 after selling out during the quarter.
  • Squarepoint sold 7,421 Genmab shares in Q3 2026, an estimated $204K.
  • Squarepoint first reported a position in Genmab in Q4 2020 and held it in 15 quarters.
  • Squarepoint's Genmab position peaked at $2.45M in Q4 2024.
  • 204 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.